Barry Greene, Sage CEO, at Endpoints #JPM23 (Adrien Villez for Endpoints News)
February 6, 2023 09:54 AM ESTUpdated 10:50 AM
FDA+

Sage, Bio­gen set their sights on a sum­mer PDU­FA dead­line as zu­ra­nolone de­ci­sion looms

John Carroll

Editor & Founder

Sage and its part­ners at Bio­gen can now mark a sum­mer date for a go/no go mar­ket­ing de­ci­sion for their block­buster de­pres­sion can­di­date, zu­ra­nolone. The …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times